Dihydroeponemycin
Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis[1].
Product Specifications
CAS Number
126463-64-7
UNSPSC
12352005
Hazard Statement
H302
Target
Apoptosis; Proteasome
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dihydroeponemycin.html
Solubility
10 mM in DMSO
Smiles
CC(C)CCCCC(N[C@@H](CO)C(N[C@@H](CC(C)C)C([C@]1(CO1)CO)=O)=O)=O
Molecular Formula
C20H36N2O6
Molecular Weight
400.51
Precautions
P264-P270-P330-P501
References & Citations
[1]Meng L, et al. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 1999;59 (12) :2798-2801.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Staphylococcus aureus Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta (accD)
Recombinant Staphylococcus aureus Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta (accD)
Recombinant Staphylococcus aureus Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta (accD)